American Journal of Cardiology
Volume 104, Issue 2 , Pages 194-198 , 15 July 2009

Usefulness of Combining Serum Uric Acid and C-Reactive Protein for Risk Stratification of Patients With Coronary Artery Disease (Bezafibrate Infarction Prevention [BIP] Study)

  • Yafim Brodov, MD, PhD

      Affiliations

    • Heart Institute, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    • ,
  • Shlomo Behar, MD

      Affiliations

    • Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    • ,
  • Ilan Goldenberg, MD

      Affiliations

    • Heart Institute, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    • ,
  • Valentina Boyko, MSc

      Affiliations

    • Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    • ,
  • Pierre Chouraqui, MD

      Affiliations

    • Heart Institute, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Corresponding Author InformationCorresponding author: Tel: 972-3-530-2109; fax: 972-3-535-3441

References 

  1. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843
  2. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565
  3. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599–2610
  4. Haim M, Benderly M, Tanne D, Matas Z, Boyko V, Fisman EZ, et al. C-reactive protein, bezafibrate, and recurrent coronary events in patients with chronic coronary heart disease. Am Heart J. 2007;154:1095–1101
  5. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?. Am J Med. 2005;118:816–826
  6. Meisinger C, Koenig W, Baumert J, Döring A. Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from the general population (The MONICA/KORA Cohort Study). Arterioscler Thromb Vasc Biol. 2008;28:1186–1192
  7. Ruggiero C, Cherubini A, Miller E, Maggio M, Najjar SS, Lauretani F, et al. Usefulness of uric acid to predict changes in C-reactive protein and interleukin-6 in 3-year period in Italians aged 21 to 98 years. Am J Cardiol. 2007;100:115–121
  8. Caravaca F, Martín MV, Barroso S, Cancho B, Arrobas M, Luna E, et al. Serum uric acid and C-reactive protein levels in patients with chronic kidney disease. Nefrologia. 2005;25:645–654
  9. Coutinho Tde A, Turner ST, Peyser PA, Bielak LF, Sheedy PF, Kullo IJ. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am J Hypertens. 2007;20:83–89
  10. Haim M, Benderly M, Tanne D, Matas Z, Boyko V, Fisman EZ, et al. C-reactive protein distribution and correlates among men and women with chronic coronary heart disease. Cardiology. 2007;107:345–353
  11. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102:2–4
  12. Rehak NN, Janes G, Young DS. Calorimetric enzymic measurement of uric acid in serum. Clin Chem. 1977;23:195–199
  13. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147
  14. Madsen TE, Muhlestein JB, Carlquist JF, Horne BD, Bair TL, Jackson JD, et al. Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease. Am J Nephrol. 2005;25:45–49
  15. Bickel C, Rupprecht HJ, Blankenberg S, Rippin G, Hafner G, Daunhauer A, et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol. 2002;89:12–17
  16. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003;107:1991–1997
  17. Høieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65:1041–1049
  18. Gerber Y, Tanne D, Medalie JH, Goldbourt U. Serum uric acid and long-term mortality from stroke, coronary heart disease and all causes. Eur J Cardiovasc Prev Rehabil. 2006;13:193–198
  19. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension (The PIUMA study). Hypertension. 2000;36:1072–1078
  20. Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) study. Ann Epidemiol. 2000;10:136–143
  21. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131:7–13
  22. De Leeuw PW, Thijs L, Birkenhäger WH, Voyaki SM, Efstratopoulos AD, Fagard RH, et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension. J Am Soc Nephrol. 2002;13:2213–2222
  23. Waring WS, Adwani SH, Breukels O, Webb DJ, Maxwell SR. Hyperuricaemia does not impair cardiovascular function in healthy adults. Heart. 2004;90:155–159
  24. Athyros VG, Mikhailidis DP, Liberopoulos EN, Kakafika AI, Karagiannis A, Papageorgiou AA, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) study. Nephrol Dial Transplant. 2007;22:118–127
  25. Hu P, Seeman TE, Harris TB, Reuben DB. Is serum uric acid level associated with all-cause mortality in high-functioning older persons: MacArthur studies of successful aging?. J Am Geriatr Soc. 2001;49:1679–1684
  26. Dawson J, Walters M. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?. Br J Clin Pharmacol. 2006;62:633–644
  27. Jee SH, Lee SY, Kim MT. Serum uric acid and risk of death from cancer, cardiovascular disease or all causes in men. Eur J Cardiovasc Prev Rehabil. 2004;11:185–191
  28. Strasak AM, Rapp K, Hilbe W, Oberaigner W, Ruttmann E, Concin H, et al. Serum uric acid and risk of cancer mortality in a large prospective male cohort. Cancer Causes Control. 2007;18:1021–1029
  29. Strasak A, Ruttmann E, Brant L, Kelleher C, Klenk J, Concin H, et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem. 2008;54:273–284
  30. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006;37:1503–1507

PII: S0002-9149(09)00721-8

doi: 10.1016/j.amjcard.2009.03.017

American Journal of Cardiology
Volume 104, Issue 2 , Pages 194-198 , 15 July 2009

Article Tools

* Image Usage & Resolution